One target, like a checkpoint inhibitor treatment has, generally has less of a chance at being effective as tissue agnostic than a time proven, by nature, properly activated, pre validated through Specials DC treatment like murcidencel/L. Maybe that’s why all the trials were done for checkpoint inhibitors and murcidencel was given a cancer indication designation for any applications for use submitted as IFRs to the NHS in the UK; ). Best wishes.
Market Data 
Markets 
AI
